1,069 Views

Instructional Course

Instructional Course - Available with the Platinum and Silver packages or Individual Course Ticket

032IC - Current Concepts and Controversies in Male Hormone Replacement Therapy

Saturday, May 14, 2022

10:00 AM – 12:00 PM

Location: Room 210

Instructional Course Director(s)

WH

Wayne John G. Hellstrom, MD (he/him/his)

Prof of Urology & Chief of Andrology
Tulane University School of Medicine, Department of Urology

Instructional Course Faculty(s)

MM

Martin M. Miner, MD

Co-Director The Men's Health Center
Men's Health Center
JM

John Patrick Mulhall, MD

Memorial Sloan Kettering Cancer Center
MK

Mohit Khera, MD

Baylor College of Medicine

Learning Objectives:

Interpret the link between hypogonadism and cardiovascular disease
Devise a cost effective-treatment and follow up algorithm for the hypogonadal male
Appraise the controversy regarding testosterone supplementation and prostate cancer

Testosterone is the primary androgenic hormone responsible for nominal growth and development of male sex organs and maintenance of secondary sex characteristics. The diagnosis of male hypogonadism depends on both a specified lab value of serum testosterone (300 mg/dl) and related clinical symptoms. There are numerous methods of testosterone replacement therapy (TRT), with the goal centered on restoring physiological androgen levels and alleviating clinical symptoms. The treatment depends on the underlying cause, but can be either gonadotropin administration or testosterone supplementation.

For the clinician, it is important to be cognizant of the current controversies regarding benign prostatic hyperplasia (BPH), prostate cancer and cardiovascular disease (coronary artery disease, myocardial infarction and sudden cardiac death). After the fundamentals of testosterone deficiency, laboratory diagnosis and guidelines are covered, individual cases representing each of the controversial areas will be covered in detail.